genelux.com - הכנסה לפני ניכוי ריבית, מסים ופחת GNLX

Genelux Corporation (GNLX) possesses a powerful scientific foundation in the creation of selective oncolytic viruses to combat solid tumors. This EBITDA chart visualizes operational efficiency dynamics, where 0.00 captures the current value of the indicator. Drug development relies on neural networks and synthesis automation, while the strategy aims to accelerate R&D testing and secure major investment partners.

For Genelux Corporation (GNLX), whose operations are limited to the clinical trial stage and strict FDA oversight, operating cash flow is driven by R&D expenses in the absence of market sales. The absolute operating profit aggregates the net financial result of operations, allowing investors to assess the real business value and the capital burn rate by tracking the trend through this absolute operating profit figure.